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FusionGlycoproteins gB and gH/gL are required for entry of Epstein–Barr virus (EBV) into cells, but the role of each
glycoprotein and how they function together tomediate fusion is unclear. Analysis of the functional homology
of gB from the closely related primate gammaherpesvirus, rhesus lymphocryptovirus (Rh-LCV), showed that
EBV gB could not complement Rh gB due to a species-speciﬁc dependence between gB and gL. To map
domains of gB required for this interaction, we constructed a panel of EBV/Rh gB chimeric proteins. Analysis
showed that insertion of Rh gB from residues 456 to 807 restored fusion function of EBV gB with Rh gH/gL,
suggesting this region of gB is important for interaction with gH/gL. Split YFP bimolecular complementation
(BiFC) provided evidence of an interaction between EBV gB and gH/gL. Together, our results suggest the
importance of a gB–gH/gL interaction in EBV-mediated fusion with B cells requiring the region of EBV gB from
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Epstein–Barr Virus (EBV) is a gammaherpesvirus that has a high
prevalence in humans, with more than 90% of the population latently
infected with the virus (Rickinson, 2007). Primary infection during
childhood is typically asymptomatic, but infection in adolescents can
result in the development of infectious mononucleosis. Virions are
transmitted through the saliva into epithelial cells of the oral pharynx,
and subsequently to resting B cells. Following this initial infection,
EBV persists in a latent state in memory B lymphocytes where it can
remain indeﬁnitely (Babcock et al., 1998; Thorley-Lawson and
Babcock, 1999). The expansion and proliferation of these cells can
lead to the development of a number of EBV-related malignancies
including Hodgkin's disease, Burkitt's lymphoma, some T-cell lym-
phomas, and tumors associated with epithelial tissues such as
nasopharyngeal carcinoma and gastric carcinoma (Rickinson, 2007).
EBV is also associated with the lymphoproliferative disorders in
immunocompromised patients, such as oral hairy leukoplakia and
post-transplant lymphoproliferative disorders (Rickinson, 2007).Entry of herpesviruses requires the concerted efforts of multiple
glycoproteins in a multi-step process that results in binding of the
virus to the cell surface, interaction with cellular entry receptors,
membrane-virion fusion, and internalization of the virion (Spear and
Longnecker, 2003). For Epstein–Barr virus (EBV), the viral glycopro-
teins required for fusion are glycoprotein B (gB), the complex of gH
and gL (gH/gL), and gp42 (Spear and Longnecker, 2003). Infection of B
cells is initiated by an interaction between glycoprotein gp350/220
and the CD21/CR2 cellular receptor (Fingeroth et al., 1984; Nemerow
et al., 1985; Tanner et al., 1987; Speck et al., 2000). Following initial
binding, viral glycoprotein gp42 binds to human leukocyte antigen
(HLA) class II molecules and triggers fusion, which is mediated by
glycoproteins gB, gH, and gL (Li et al., 1997; Speck et al., 2000). The
mechanism of infection of epithelial cells by EBV is less clear, though it
has recently been found that fusion is triggered upon binding of gH/gL
with cellular integrins αvβ6 or αvβ8 (Chesnokova et al., 2009).
Glycoprotein gB and the heterodimer gH/gL constitute the conserved
fusion machinery that is required for fusion of the virion and cell
membrane across all members of the herpesviridae (Spear and
Longnecker, 2003; McShane and Longnecker, 2004). However, the
mechanism of how these glycoproteins function to mediate fusion is
still unclear and the subject of much investigation.
Glycoprotein B is highly conserved throughout the herpesvirus
family, and has been shown to be an essential component of virus-cell
fusion (Spear and Longnecker, 2003). The crystal structure of EBVgB in a
presumed postfusion trimer conformation was recently reported and
Fig. 1. Fusion is blocked by EBV gB and Rh gL co-expression. Fusion function of EBV and
Rh-LCV glycoproteins with B cells. (A) CHO-K1 cells were transiently transfected with
all of the EBV glycoproteins necessary for fusion (gp42, gB, gH, and gL) or the indicated
Rh-LCV glycoprotein. Effector CHO-K1 cells were overlaid with target Daudi B cells and
luciferase activity was measured. Luciferase activity was normalized to wild-type EBV
levels, which was set to 100%. (B) CHO-K1 cells were transiently transfected with all of
the Rh-LCV glycoproteins necessary for fusion (gp42, gB, gH, and gL) or the indicated
EBV glycoprotein. Effector CHO-K1 cells were overlaid with target Daudi B cells and
luciferase activity was measured. Luciferase activity was normalized to wild-type Rh-
LCV levels, which was set to 100%.
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for mediating fusion (Backovic et al., 2009). Based on the distinct
structural properties of the glycoprotein, EBV gB was added to the class
III group of viral fusion proteins that previously included glycoprotein G
of Vesicular Stomatatis virus (VSV) and glycoprotein B of Herpes
Simplex virus 1 (HSV-1) (Heldwein et al., 2006; Roche et al., 2006;
Backovic and Jardetzky, 2009). The fusion domain of gB contains the two
putative fusion loops that are thought to insert into the target
membrane through a conformational change that brings about fusion
between the two membranes. Mutagenic analysis of the hydrophobic
residues within the putative fusion loops of EBV and HSV-1 gB
signiﬁcantly reduced fusion function, demonstrating that the putative
fusion loops are essential for the ability of gB tomediate fusion (Backovic
et al., 2007; Hannah et al., 2007, 2009). These studies, as well as others,
have demonstrated that gB is likely the major fusogen that mediates
fusion of the virion and cell membrane. However, a distinct deviation
from other class III fusion proteins is that EBV and HSV-1 gB require the
gH/gL complex for virus entry.
A central focus in understanding the entry of herpesviruses is
deciphering the interactions that occur between viral glycoproteins and
how these associations drive fusion. Much of our present knowledge on
this matter has come from studies of HSV-1. In addition to interactions
between the HSV-1 viral glycoproteins gD and gH/gL and gD and gB, a
direct interaction between glycoproteins gB and gH/gL was detected
using split ﬂuorescence bimolecular ﬂuorescence complementation
(BiFC) assays (Atanasiu et al., 2007; Avitabile et al., 2007). For EBV,
evidence for an interaction between gB and gH/gL ﬁrst came from a
study of gL from the closely related rhesus lymphocryptovirus (Rh-LCV)
that suggested the role of gL in fusion involves the activation or
recruitment of gB with the gH/gL complex (Omerovic and Longnecker,
2007; Plate et al., 2009). The Rh-LCV glycoproteins share a high
sequence similarity with EBV but Rh gL could notmediate fusionwith B
cells when paired with EBV gB. However, a complete restoration of the
fusion function of Rh gL was observed when paired with Rh gB,
demonstrating a species-speciﬁc reliance between these two glycopro-
teins that are essential for fusion. The essential dependence between gB
and gL was used to map the regions and speciﬁc amino acid residues of
gL that are necessary formediating fusion functionwith gB. Subsequent
studies found that EBV gB was unable to mediate B cell fusion when
expressed with the Rh-LCV glycoproteins necessary for fusion (gp42,
gH, and gL) while expression of all Rh-LCV glycoproteins together
mediated fusion with B cells very efﬁciently. Given that the sequence
similarity between EBV and Rh gB is near 86%, we hypothesized that
regions of gB essential formediating fusion functionwithgH/gL couldbe
identiﬁed using chimeric EBV/Rh gB proteins.
The objective of this study was to further analyze the interaction
between gB and gH/gL in EBV and Rh-LCV andmap regions of gB that are
involved in the interaction with gH/gL. Analysis of the EBV/Rh gB
chimeras in the cell–cell fusion assay identiﬁed the region from residues
456 to 807 as being important for a functional interaction with gH/gL,
with evidence that sites from both regions 456–628 and 628–807 are
required. Further analysis of chimeras usingBiFC conﬁrmed that insertion
of these regionsofRhgB intoEBVgBcouldmodestly enhance the abilityof
EBV gB to interact with Rh gH/gL. These results provide further evidence
of an interactionbetweengBandgH/gLandhighlights that thereare likely
multiple domains of gB required for an interaction with gH/gL.
Results
Rh-LCV gB does not complement EBV gB for fusion function
The glycoproteins of the closely related EBV and Rh-LCV share a
high degree of sequence homology and have proven to be a useful tool
in studying the required domains for glycoprotein fusion function.We
previously found that Rh gL can only mediate fusion with EBV
glycoproteins when expressed together with Rh gB, suggesting thatthere is a species-speciﬁc dependence between gL and gB that is
necessary for these two glycoproteins to mediate fusion together
(Omerovic and Longnecker, 2007; Plate et al., 2009).
To examine the dependence between gB and gL in mediating
fusion with B cells further, we examined the functional homology of
gBs from EBV to the closely related Rh-LCV. Similar to what we
previously found (Omerovic and Longnecker, 2007; Plate et al.,
2009) but somewhat different from others (Wu and Hutt-Fletcher,
2007), fusion with EBV gp42, gB, and gH and Rh gL was near
background levels while fusion with EBV gp42, gH, and Rh gL and
gB was restored to wild-type EBV fusion activity (Fig. 1A). Rh-LCV
has been shown to infect human B cells in vitro (Moghaddam et al.,
1998) so it was not surprising that expression of Rh gp42, gB, gH,
and gL can also mediate fusion with B cells in our cell-based fusion
assay (Fig. 1B, column 1). However, the ability of the Rh-LCV
glycoproteins to mediate fusion was signiﬁcantly reduced when EBV
gB was expressed in place of Rh gB (Fig. 1B, column 2). This
observation is in agreement with our previous conclusion that there
is a species-speciﬁc dependence between gB and gL, and the
inability to mediate fusion is speciﬁcally due to the expression of
EBV gB with Rh gL. This is further supported by the ﬁnding that
fusion of the Rh-LCV glycoproteins with EBV gB is enhanced when
EBV gL is expressed with EBV gB (Fig. 1B, column 3).
Interestingly, we found that Rh gB is functional inmediating fusion
with EBV glycoproteins gp42, gH, and gL (Fig. 1A, column 4). This
ﬁnding would suggest that Rh gB can interact with EBV gH/gL while
the converse, an interaction between EBV gB with Rh gH/gL, does not
occur.
28 A.E. Plate et al. / Virology 413 (2011) 26–38Generation of EBV/Rhesus chimeric gB glycoproteins
It is intriguing that EBV gB cannot substitute for Rh gB inmediating
fusion with the Rh-LCV glycoproteins since these two proteins are
extremely homologous, sharing about 86% sequence similarity. The
amino acid sequence alignment of EBV and Rh gB is shown (Fig. 2A)
and highlights that many features of gB are conserved between these
two closely related glycoproteins. The position of the signal sequence,
sites of predicted glycosylation, disulﬁde bonding, furin cleavage and
predicted structural domains are shown. The three asparagine
residues 163, 290, and 629, that are likely N-glycosylated in EBV gB
(shown Figs. 2A and C, blue asterisks) are conserved in Rh gB and are
also likely N-glycosylated to yield themature, functional glycoprotein.
In EBV gB, 4 conserved cysteines are predicted to form 2 disulﬁde
bonds, between Cys68-Cys484 and Cys522-588 (Backovic et al.,
2009). In Rh gB, these bonds are likely conserved and predicted to
form between Cys68-489 and Cys556-Cys592 (Figs. 2A and C, pink
asterisks). A stretch of ﬁve arginine residues (428–432) that form a
cleavage site important for EBV fusion are also conserved between
EBV and Rh gB (Fig. 2A) (Sorem and Longnecker, 2009). The six
hydrophobic residues in EBV gB that form the putative fusion loops
(FL) that facilitate interaction with target membranes, WY112–113 and
WLIW193–196, are also highly conserved in Rh gB. The residues
corresponding to EBV FL1 and FL2 in Rh gB are WY112–113 and
WILW193–196 (Figs. 2A and C, purple brackets). Due to the high degree
of sequence similarity, as well as the conservation of predicted
features, we predicted that a majority of the EBV/Rh gB chimeras
would be properly processed and could assist in the identiﬁcation of
regions important for fusion function of gB in concert with gH/gL.
To map regions of gB critical for fusion function with gH/gL,
chimeras were generated that contain regions of both Rh and EBV gB.
Chimeras were constructed using EBV gB as the backbone, with
varying regions of Rh gB replacing the corresponding region in EBV gB
(Fig. 2B). The regions of EBV gB were removed using two preexisting
restriction sites. Regions of Rh gB from residues 1 to 628, 1 to 807, and
628 to 807 were isolated using restriction sites that were common for
both EBV and Rh gB. Regions of Rh gB from residues 1 to 254, 254 to
346, 1 to 346, 346 to 456, 254 to 628, 346 to 628, and 456 to 807 were
ampliﬁed using oligonucleotides containing the unique restriction
sites for EBV gB. The generated chimeras cover a majority of the
ectodomain of gB in overlapping fragments that span regions of high
sequence similarity as well as less conserved regions.Expression and cellular localization of EBV/Rhesus gB chimeras
The protein expression of the EBV/Rh gB chimeras was examined
by transient expression of the constructs in CHO-K1 cells. Analysis of
expression by western blot showed that all chimeras were expressed,
although Rh gB and some of the chimeras were expressed at slightly
lower levels (Fig. 3, top panel). Whether this is due to a reduction inFig. 2. EBV and Rh-LCV gB amino acid sequence alignment, schematic diagram of EBV/Rh
interaction on the EBV gB crystal structure. (A) The 857 amino acid EBV gB sequence (acces
YP_068009) were aligned using the MultiAlin program. Nonconserved residues between EBV
grey and the transmembrane (TM) domain is depicted by the gray bracket. Residues mod
residues that form the putative furin cleavage site are highlighted in green. The conserved cy
gB are highlighted in magenta with asterisks. The known fusion loops residues (WY and W
highlighted with purple brackets to show both fusion loop 1 (FL1) and 2 (FL2). (B) Chimeri
(dark grey). The amino acid residues of Rh gB insertions are indicated above each chimera.
Nonconserved amino acid residues between EBV gB and Rh gBweremapped onto the EBV gB
within the EBV gB amino acid sequence. (C) The structure of the EBV ectodomain is colored fr
indicate the location of the Asn residues that aremodiﬁed by N-linked glycans, which are sho
loops (FL) in purple. (D) Rh gB amino acid residues 456–628 correspond to EBV gB residu
residues in this region are indicated in red based on the residue location in the EBV gB amino
structure that exhibited discontinuous electron density of lower quality and were omitted fr
807 correspond to EBV gB residues 623–800 are colored blue on the cartoon structure of EBV
outside of the crystallized gB ectodomain and only residue 627 is shown.protein expression or a slight impairment of the EBV gB rabbit
polyclonal antibody to recognize Rh gB is not clear.
EBV gB predominantly localizes to the perinuclear region of cells
(Gong et al., 1987; Gong and Kieff, 1990), but small amounts of gB can
be detected at the cell surface using biotinylation of cell surface
proteins, followed by western blot analysis (Backovic et al., 2007;
Reimer et al., 2009). Presence of EBV and Rh gB and the EBV/Rh gB
chimeras on the cell surface was analyzed using sulfosuccinimidyl-1-
6-(biotinamido)hexanoate as previously described (Reimer et al.,
2009). All EBV/Rh gB chimeras and wild-type Rh gB were expressed
on the cell surface at levels similar to wild-type EBV gB (Fig. 3 middle
panel). This result indicates the variability of gB reactivity in the
whole cell lysates in the top panel of Fig. 3 is likely not signiﬁcant.
Herpes simplex virus (HSV) gB has been shown to form oligomers
in vivo (Claesson-Welsh and Spear, 1986; Grunewald et al., 2003) and
the crystallized ectodomains of EBV and HSV gB formed trimers
(Backovic et al., 2009; Heldwein et al., 2006), suggesting that the
formation of gB oligomers is a common feature in herpesviruses. A
previous study of EBV gB found that mutants that could not
oligomerize did not mediate fusion with epithelial or B cells (Reimer
et al., 2009). Therefore, the formation of oligomers was analyzed in
whole cell lysates for EBV gB, Rh gB, and the EBV/Rh gB chimeras using
SDS-PAGE under non-reducing conditions. While detection of
oligomers was reduced for Rh gB, all EBV/Rh gB chimeras were able
to form higher molecular weight oligomers similar to EBV gB (Fig. 3,
bottom panel bracket).
The apparent molecular weight of EBV gB has been shown to vary,
depending on the amount of glycosylation the protein undergoes
during maturation and processing (Emini et al., 1987; Gong et al.,
1987; Papworth et al., 1997; Lee, 1999). While EBV gB is typically
reported as a 110-kDa protein, the presence of a higher molecular size
gB variant that migrates just above monomeric gB was reported and
shown to be functionally important for fusion (Reimer et al., 2009).
This N-glycosylated modiﬁed form of monomeric gB likely represents
the fully mature form of EBV gB. EBV/Rh gB chimeras that contain
insertions of Rh gB in the amino terminus, ERh gB (1–254) and ERh gB
(1–346), did not exhibit this higher molecular size band above
monomeric gB (Fig. 3, closed arrows). The EBV/Rh gB chimera that
contains the small portion of Rh gB from residues 254 to 346 was
variable in the expression of the higher molecular size form of gB, and
when detected migrated at a smaller molecular size than that for EBV
gB and the other chimeras (compare bands indicated by closed arrows
in middle and bottom panel). This chimera, as well as the other two
chimeras that lack the variant band of gB, were unable to mediate
fusion with either the EBV or Rh-LCV glycoproteins. As the function of
these three EBV/Rh gB chimeras is likely hampered by the improper
processing and maturation of gB, we did not examine their functional
properties further.
While EBV gB is primarily localized to the perinuclear membrane
and the endoplasmic reticulum, the EBV gH/gL complex is largely
detected at the cell surface (Gong et al., 1987; Gong and Kieff, 1990;-LCV gB chimeras, and location of nonconserved residues implicated in the gB–gH/gL
sion number YP_401713) and 864 amino acid Rh-LCV gB sequence (accession number
and Rh-LCV are highlighted in red. The 22 amino acid signal sequence is highlighted in
iﬁed by N-linked glycans are highlighted in blue with asterisks and the ﬁve arganine
steine residues that were shown to form disulﬁde bonds in the crystal structure of EBV
LIW) of EBV gB and the predicted fusion loop residues (WY and WILW) of Rh gB are
c EBV/Rh gB proteins were generated using regions from Rh gB (light grey) and EBV gB
The location of the signal sequence (ss) and transmembrane (TM) domains are shown.
crystal structure using PyMol. The numbers indicate the Rh-LCV amino acid substitution
om blue to red, with the ﬁve domains labeled by roman numerals I through V. Numbers
wn in blue. Cysteine residues that form disulﬁde bonds are shown inmagenta and fusion
es 451–623 and are colored green on the cartoon structure of EBV gB. Nonconserved
acid sequence (459, 508, 512, 513, 591, 606, and 609). Residues located in regions of the
om the gB structure are not shown (549, 587, and 589). Rh gB amino acid residues 628–
gB. Most of the nonconserved residues between EBV and Rh gB in this region are located
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Fig. 3. Expression levels of most of the EBV/Rh gB chimeras are similar to that of EBV gB. CHO-K1 cells were transfected with EBV gB, Rh-LCV gB, and the EBV/Rh gB chimeras as
described in Materials and Methods. (A) Western blot analysis of EBV/Rh gB chimera expression in whole cell lysates was determined under reducing conditions. Molecular weight
marker in kDa is indicated and the open arrow indicates the position of full length EBV gB. (B) The cell surface expression of EBV/Rh gB chimeras was determined by biotinylation of
cell membranes followed by immunoprecipitation with a monoclonal gB antibody. Western blot analysis of EBV/Rh gB chimeras was done under non-reducing conditions with a
polyclonal gB antibody. Molecular weight marker in kDa is indicated and the open arrow indicates the position of full length EBV gB. (C) Oliogomer formation of EBV/Rh gB chimeras
was examined in whole cell lysates under nonreducing conditions. Oligomers are identiﬁed by brackets to the right of the blot, monomeric gB is indicated by an open arrow, and the
fully glycosylated mature form of gB indicated by a closed arrow.
30 A.E. Plate et al. / Virology 413 (2011) 26–38Hutchinson et al., 1992; Li et al., 1995; Lee, 1999; Neuhierl et al.,
2002). Expression of the glycoproteins together in cells does not alter
the localization of either gB or the gH/gL complex. Immunoﬂuores-
cence analysis of the Rh-LCV glycoproteins conﬁrmed that Rh gB and
gH/gL have the same cellular localization as EBV gB and gH/gL
(Figs. 4A and B). We then examined the intracellular expression of Rh
gB, EBV gB, and the EBV/Rh gB chimeras to determine if localization
was disrupted for the chimeras. The EBV/Rh gB chimeras localized
predominantly to the perinuclear membrane and endoplasmic
reticulum, similar to what was observed for both EBV and Rh gB
(Fig. 4). The localization of Rh gH/gL was not altered upon expression
of the EBV/Rh chimeras. In summary, analysis of expression and
localization showed that eight of the EBV/Rh gB chimeras were
expressed intracellularly and at the cell membrane, processed to yield
a fully glycosylated mature form of gB, formed higher molecular
weight oligomers and were properly localized within transfected
cells.
Evaluation of the ability of EBV/Rh gB chimeras to mediate fusion with B
cells
In the current study, we found that Rh gB is able to mediate fusion
when expressed with the EBV glycoproteins, demonstrating that Rh
gB does not have the same species speciﬁcity as EBV gB. This
observation provides a means of testing the general fusion function of
the chimeras. Since both EBV gB and Rh gB mediate fusion with the
EBV glycoproteins, we would expect the EBV/Rh gB chimeras to also
function in fusion if they are properly processed. Fusion of the effectorand target cells led to the expression of luciferase, which was
quantiﬁed and normalized to the EBV wild-type level, set at 100%
fusion activity. As expected, all of the EBV/Rh gB chimeras were able to
mediate fusion with EBV glycoproteins at levels near or above EBV gB
(Fig. 5A). As we have previously observed, Rh gBmediates fusion with
B cells at levels above wild-type EBV gB and therefore fusion activity
of EBV/Rh gB chimeras containing larger portions of Rh gB also elicited
fusion at levels above wild-type EBV gB. While these results do not
elucidate regions of gB that are essential for mediating fusion in
complex with gH/gL, we veriﬁed that the EBV/Rh gB chimeras that are
properly processed to yield the fully glycosylated mature form of gB
are also likely in the correct structural conformation to allow gB to
execute fusion.
To identify regions of gB that are essential for fusion function with
gH/gL, the EBV/Rh gB chimeras were tested in the cell–cell fusion
assay with the Rh-LCV glycoproteins. As we predict that certain gB
residues are critical for fusion function with gH/gL, chimeras that
contain essential Rh gB domains are predicted to be active for fusion
with Rh gH/gL. As previously observed, EBV gB cannot mediate B cell
fusion when expressed with Rh gp42, gH, and gL (Fig. 5B, ﬁrst
column). The level of fusion with EBV gB is roughly 10% of the level of
wild-type Rh gB fusion and similar to vector only control. Insertion of
a majority of the Rh gB sequence from residues 1 to 807 into EBV gB
fully restored fusion function of EBV gB to 99% of wild-type Rh gB. This
region includes the transmembrane domain and the ﬁrst 69 amino
acids of the cytoplasmic tail. Insertion of the Rh gB sequence from
residues 1 to 628 only restored fusion function of EBV gB to 33% of
wild-type Rh gB, suggesting that the region from 628 to 807 is essential
Fig. 4. Cellular localization of EBV/Rh gB chimeras and Rh gH/gL is similar to wild-type gB. CHO-K1 cells were transfected with Rh-LCV gH/gL and either EBV gB (A), Rh gB (B), or the
indicated EBV/Rh gB chimera (C–J). Cells were ﬁxed at 24 h after transfection and immunostained using the monoclonal E1D1 gH/gL speciﬁc antibody (green channel) and the
polyclonal gB antibody (red channel) with DAPI nuclear staining.
31A.E. Plate et al. / Virology 413 (2011) 26–38for the fusion function observed with the chimera containing Rh gB
residues 1–807. Insertion of Rh gB residues 456–807 signiﬁcantly
restored fusion function, mediating fusion at 70% of the level of wild-
type Rh gB. Interestingly, insertion of Rh gB residues 456–628 or 628–
807 resulted in a restoration of fusion function to 30% or 20%,
respectively. This observation indicates that sites from both regions
are important for fusion function with gH/gL, since one region alone is
insufﬁcient to signiﬁcantly restore fusion. The region between residues
456 and 807 is highly conserved between EBV and Rh gB, with almost
93% sequence similarity. The remaining chimeras that contain Rh gB
residues 346–456, 254–628, and 346–628 did not signiﬁcantly restore
fusion function of EBV gB with B cells, indicating that these regions are
likely not important for gB fusion function with gH/gL.
Location of non-conserved residues important for gB and gH/gL fusion
function
There are 25 nonconserved amino acid residues between EBV and
Rh gB between residues 456 and 807; with 10 nonconserved residues
present in the region from 456 to 628, and the remaining 15 in the
region from residues 628 to 807. To analyze the location of residues
that may be important for fusion function with gH/gL, the crystal
structure of the EBV gB ectodomain from residues 23 to 685 was used
to illustrate nonconserved residues between EBV and Rh gB. The 10
nonconserved residues between EBV and Rh gB from 456 to 628 are all
located in domains III and IV of EBV gB (Fig. 2D).
The most prominent element of domain III is the long central
alpha-helix that spans 42 residues, which is highly conserved
between Rh and EBV gB. There is a single amino acid variation at
the base of this αC-helix at valine residue 459 of EBV gB that is an
isoleucine at residue 464 of Rh gB. The serine at residue 508 of EBV gB,
located in the αD-helix, is a glycine at that residue in Rh gB. The two
remaining amino acid variations in domain III of EBV gB, a lysine at
residue 512 and alanine at 513, are both located in a turn that
connects the αD-helix and the β24 strand.
Domain IV of EBV gB is composed entirely of β-sheets, and appears
more disordered than the same domain in HSV-1 gB. The threonine at
residue 591 of EBV gB is a serine residue in Rh gB and is located just
beyond the disordered region between the β30 and β31 strands. The
asparagine at residue 606 and the histidine at residue 609 of EBV gB
are located at the end of the β32 and beginning of the β33 strands,
respectively. Interestingly, the DY residues that are located in the turn
between nonconserved residues 606 and 609 are highly conservedacross many herpesviruses, including HSV-1 and 2, CMV, and HHV-6
and 8 (Backovic et al., 2009). The three remaining nonconserved
residues at 549, 587, and 589 are located in areas of EBV gB that were
omitted from the ﬁnal crystal structure.
The 15 nonconserved residues between EBV and Rh gB from 628 to
807 are located outside of the crystallized gB ectodomain, with the
exception of the serine at residue 627 of EBV gB. This residue is located
in domain V, before the αE and αF C-terminal helices, and is an
alanine at the corresponding residue in Rh gB (Fig. 2D).Generation and characterization of EBV and Rh-LCV glycoproteins in
bimolecular ﬂuorescence complementation (BiFC) assay
To speciﬁcally address the interaction of EBV gB and gH/gL, we
utilized the BiFC assay that was previously used to demonstrate the
interaction between HSV-1 gB and gH/gL (Atanasiu et al., 2007;
Avitabile et al., 2007). BiFC utilizes a ﬂuorescent protein that has been
split into the amino and carboxyl terminal halves and thus no longer
produces ﬂuorescence. By fusing each of the two non-ﬂuorescent
fragments to putative interacting partners, restoration of ﬂuorescence
provides visual evidence of a protein–protein interaction (Kerppola,
2006a, 2006b, 2006c). The amino and carboxy terminal fragments of
the YFP-variant Venus ﬂuorescent protein (YFPN or YFPC) were fused
in frame to the carboxy terminus of EBV glycoproteins gB and gH and
Rh gH (Fig. 6A) (Nagai et al., 2002). Western blot analysis of cells
transfected with the YFP-tagged glycoproteins showed that the
electrophoretic mobility of the constructs was increased relative to
wild-type, as expected (Fig. 6A). Depending on the construct
examined, variable levels of fusion activity were observed when the
YFP-tagged glycoproteins were examined in the cell–cell fusion assay.
A signiﬁcant reduction in fusion function was observed when the split
YFP-tagged gBs were analyzed in the cell–cell fusion assay, with levels
close to background (data not shown). In contrast, the fusion function
of EBV gH and Rh gH YFP-tagged constructs were less impaired, with
fusion levels near 50% or 100%, respectively. Previous studies have
indicated that the EBV gB cytoplasmic tail is an important determi-
nant of fusion function and the YFP tag may be interfering with this
function. However, our analysis shows that the YFP-tagged gB
constructs form oligomers, demonstrating that protein–protein
interactions are not impaired and the structure of gB is maintained.
Due to the impairment of fusion activity, the BiFC analysis we
performed was not in the context of EBV-mediated fusion and was
Fig. 5. Fusion functions of EBV/Rh gB chimeras with EBV and Rh-LCV glycoproteins. (A) CHO-K1 cells were transiently transfected with all of the EBV glycoproteins necessary for
fusion (gp42, gB, gH, and gL) or the indicated EBV/Rh gB chimera. Effector CHO-K1 cells were overlaid with target Daudi B cells and luciferase activity was measured. Luciferase
activity was normalized to wild-type EBV levels, which was set to 100%. (B) (A) CHO-K1 cells were transiently transfected with all of the Rh-LCV glycoproteins necessary for fusion
(gp42, gB, gH, and gL) or the indicated EBV/Rh gB chimera. Effector CHO-K1 cells were overlaid with target Daudi B cells and luciferase activity was measured. Luciferase activity was
normalized to wild-type Rh-LCV levels, which was set to 100%.
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transfected cells.
To analyze homologous glycoprotein interactions, CHO-K1 cells
were transfected with each of the glycoprotein constructs alone or
with their corresponding YFP pair. As expression of gH and gL
together is necessary for the proper processing and transport of the
gH/gL complex, wild-type EBV or Rh gL was transfected in all samples
that contained the corresponding YFP-tagged gH construct. Following
a 20-hour transfection, the cells were ﬁxed and stainedwith either the
polyclonal gB antibody or monoclonal E1D1 gH/gL antibody. In cells
that expressed single glycoprotein constructs, expression of all the gB
and gH constructs was detected by antibody staining (Figs. 6B–D,
bottom panels). No ﬂuorescence in the YFP channel was detected in
any cell expressing a single construct (Figs. 6B–D, top panels). Sinceprevious analysis has shown that EBV gB forms oligomers, we
predicted that an interaction between gB constructs would allow
the two YFP fragments to reform. A strong YFP signal was detected in
cells transfected with both EBV gB-YFPN and EBV gB-YFPC constructs,
demonstrating that the interaction between gB constructs was
sufﬁcient to permit BiFC (Fig. 6B, top panel). Interestingly, coexpres-
sion of the EBV gH-YFP constructs together with EBV gL did not result
in YFP ﬂuorescence, suggesting that the EBV gH/gL complex does not
form oligomers (Fig. 6C, top panel). A similar result was found when
the Rh gH-YFP constructs were expressed together with Rh gL
(Fig. 6D, top panel). These results are in contrast to what is observed
for HSV-1 gH/gL oligomer formation using BiFC (Atanasiu et al., 2007),
which suggests that the formation of gH/gL oligomers may be unique
to speciﬁc herpesvirus subgroups.
Fig. 6. Generation and characterization of EBV and Rh-LCV BiFC constructs. (A) Schematic diagram of EBV gB, EBV gH, and Rh gH with the N- and C-terminal fragments of Venus YFP
and western blot analysis. CHO-K1 cells were transfected with EBV gB, EBV gH/gL, Rh gH/gL and the YFP-tagged constructs. Cell lysates were analyzed using the polyclonal gB
antibody for EBV gB and gB-YFP constructs. CHO-K1 cells expressing EBV gH/gL, Rh gH/gL, and gH-YFP constructs were biotinylated as previously described and cell lysates analyzed
using the HRP conjugated Avidin antibody. (B–D) Homologous glycoprotein interactions. (B) CHO-K1 cells were transfected with EBV gB-YFPN, EBV gB-YFPC, or both constructs
together. Cells were ﬁxed, permeabilized and stained with the polyclonal gB antibody and analyzed for gB expression (red channel) and YFP ﬂuorescence (green channel) with DAPI
staining of nuclei (blue channel). (C) CHO-K1 cells were transfected with EBV gH-YFPN, EBV gH-YFPC, or both constructs together with EBV gL. Cells were ﬁxed, permeabilized and
stained with the monoclonal E1D1 gH/gL antibody and analyzed for gH/gL expression (red channel) and YFP ﬂuorescence (green channel). All confocal images were taken at 40×
magniﬁcation. (D) CHO-K1 cells were transfected with Rh gH-YFPN, Rh gH-YFPC, or both constructs together with Rh gL. Cells were ﬁxed, permeabilized and stained with the
monoclonal E1D1 gH/gL antibody and analyzed for gH/gL expression (red channel) and YFP ﬂuorescence (green channel) with DAPI staining of nuclei (blue channel). All confocal
images were taken at 40× magniﬁcation.
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K1 cells were transfected with the EBV gB-YFPN and EBV gH-YFPC
constructs together with EBV gL. Following the 20 h transfection, the
cells were ﬁxed and stained with both the polyclonal gB antibody and
monoclonal E1D1 gH/gL antibody. Bright YFP ﬂuorescence was
observed in cells that expressed both gB and gH/gL constructs,
indicating that an interaction between the two glycoproteins was
mediating BiFC (Fig. 7A, left panel). To determine if the reduction of
fusion functionwhen EBV gB is expressed with the Rh gH/gL complex is
due to an impairment in the ability of these glycoproteins to interact,
the EBV gB-YFPN construct was transfected with the Rh gH-YFPC
construct together with Rh gL. There was a noticeable decrease in the
YFP ﬂuorescence, both in the number of cells expressing YFP and the
intensity of YFP ﬂuorescence (Fig. 7A, right panel). To quantify the BiFC
results, multiple ﬁelds of cells from two separate experiments were
counted to establish the number of cells expressing gB, gH/gL, and YFP
ﬂuorescence. The percentage of YFP cells was then calculated based on
the total number of cells stained with both the gB or gH/gL antibody.
The data is summarized in Table 1. Based on the quantitative analysis of
the gB–gH/gL interaction, there was a reduction in the percentage of
YFP cells for EBV gB–YFPN with Rh gH/gL-YFPC by 15% (83%–68%).Generation and characterization of EBV/Rh gB chimeras in BiFC assay
Analysis of EBV/Rh gB chimeras in the fusion assay identiﬁed the
region of Rh gB from residues 456 to 807 as essential for mediating
fusion with the Rh gH/gL complex. To further characterize the region
of gB necessary for fusion function with gH/gL, we generated EBV/Rh
gB chimeric constructs containing the N-terminal fragment of YFP for
analysis in the BiFC assay. For this analysis, we used EBV gB YFPN
constructs that contained the regions of Rh gB from 1 to 807, 456 to
807, 456 to 628, and 628 to 807.
The ability of the EBV/Rh gB-YFPN chimeras to mediate BiFC was
ﬁrst examined in association with the EBV gH/gL-YFPC complex. All of
the EBV/Rh gB chimeras can mediate fusion with the EBV gH/gL
complex so we would expect the YFPN-tagged version would also be
capable of interacting with the YFPC-tagged gH/gL complex. In cells
expressing each of the EBV/Rh gB-YFPN constructs and EBV gH/gL-
YFPC, bright YFP ﬂuorescence was observed in a large percentage of
transfected cells (Figs. 7C–F, left panels). Upon quantifying the
number of YFP expressing cells, we found the percentage of YFP
stained for gB and gH/gL was near or above the levels observed for
EBV gB-YFPN with EBV gH/gL-YFPC (Fig. 7B). All of the EBV/Rh gB-
Fig. 7. Analysis of glycoprotein interactions by BiFC assay. Interactions between YFP-tagged gB and gH/gL were detected using BiFC (green channel). CHO-K1 cells were transfected
with the indicated YFP-tagged glycoprotein pairs for 20 h, ﬁxed, permeabilized and stained with the polyclonal gB antibody (purple channel) and monoclonal E1D1 gH/gL antibody
(red channel) with nuclei stained with DAPI (blue channel). All confocal images were taken at 40× magniﬁcation. (A) Glycoprotein interactions between EBV gB-YFPN and EBV gH/
gL-YFPC are exhibited by YFP ﬂuorescence (left panel). A weaker interaction between EBV gB-YFPN and Rh gH/gL-YFPC is exhibited byminimal YFP ﬂuorescence (right panel). (B–D)
Glycoprotein interactions between EBV/Rh gB-YFPN chimeras and EBV gH/gL-YFPC (left panels) or Rh gH/gL-YFPC (right panels) is exhibited by YFP ﬂuorescence.
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verifying that these constructs are able to form gB oligomers (data not
shown).
We then examined the ability of the EBV/Rh gB-YFPN chimeras to
mediate BiFC in association with Rh gH/gL-YFPC. While all of the EBV/
Rh gB-YFPN chimeras were able to mediate BiFC at moderate levels,
there were subtle variations between chimeric gBs. We observed the
highest level of YFP ﬂuorescence when the EBV/Rh (1–807) gB-YFPNchimera was expressed with Rh gH/gL-YFPC, near levels detected for
the EBV gB–gH/gL interaction (Fig. 7C, right panel). The lowest level of
YFP ﬂuorescence was observed for the EBV/Rh (628–807) gB-YFPN
chimera, with only 59% of dual labeled cells expressing YFP (Table 1).
Insertion of the region from 456 to 807 of Rh gB resulted in a modest
enhancement in the ability to mediate BiFC with the Rh gH/gL
complex. The percentage of YFP cells observed for the interaction of
EBV/Rh (456–807) gB-YFPN with Rh gH/gL-YFPC increased by 11%
Table 1
Quantiﬁcation of glycoprotein interactions by BiFC assay. Quantiﬁcation of gB–gH/gL
interactions. For each of the glycoprotein combinations, the number of cells expressing
gB, gH/gL, and YFP were counted from two separate experiments. A ratio of the number
of YFP cells to the number of total cells expressing gB and gH/gL was calculated and
presented as a percentage.
gB construct gH/gL # YFP cells
# gB and gH/gL
stained (%)
EBV gBN EBV gHC EBV gL 83
EBV/Rh (456–628) gBN EBV gHC EBV gL 93
EBV/Rh (456–807) gBN EBV gHC EBV gL 84
EBV/Rh (628–807) gBN EBV gHC EBV gL 83
EBV/Rh (1–807) gBN EBV gHC EBV gL 93
EBV gBN Rh-LCV gHC Rh-LCV gL 68
EBV/Rh (456–628) gBN Rh-LCV gHC Rh-LCV gL 72
EBV/Rh (456–807) gBN Rh-LCV gHC Rh-LCV gL 79
EBV/Rh (628–807) gBN Rh-LCV gHC Rh-LCV gL 59
EBV/Rh (1–807) gBN Rh-LCV gHC Rh-LCV gL 91
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interaction.
Discussion
We used functional analysis of chimeric proteins and BiFC to
provide further evidence of an interaction between gB and gH/gL. EBV
gB cannot functionally complement Rh gB and as a result does not
mediate fusion with Rh gH/gL. However, a chimeric form of EBV gB
that contained domains of Rh gB restored fusion with Rh gH/gL.
Speciﬁcally, the region from residues 456 to 807 of Rh gB was critical
in mediating fusion with Rh gH/gL and is likely important for an
interaction between gB and gH/gL.
Of the lymphocryptoviruses within the gammaherpesvirus sub-
group, the viruses that infect humans (EBV) and primates (Rh-LCV)
are the most closely related, sharing a high sequence similarity,
similar genome organization, biological properties, epidemiology, and
pathogenesis (Moghaddam et al., 1998; Cho et al., 1999; Wang et al.,
2001; Rivailler et al., 2002a, 2002b, 2004). Rh-LCV has been extremely
useful in complementation studies with EBV to identify functional
domains of the glycoproteins necessary for EBV-mediated fusion
(Omerovic and Longnecker, 2007; Wu and Hutt-Fletcher, 2007; Plate
et al., 2009). The glycoproteins that make up the core fusion complex
for herpesviruses; gB, gH, and gL, share a sequence similarity with Rh-
LCV of 86%, 85%, and 82%, respectively (Rivailler et al., 2002b). In the
current study, we found that EBV gB could not substitute for Rh gB to
mediate fusion with Rh gH/gL. However, by replacing a portion of EBV
gB with Rh gB, fusion function was restored. Together, these studies
demonstrated that amino acid changes in gB and gL can alter theirTable 2
Summary of results.
Region of Rh gB
inserted in EBV gB
Expression similar
to WT gB
Higher molecular
size gB variant
Fusion with
EBV gH/gLa
1–254 Yes No 8
254–346 Yes Variant 16
1–346 Yes No 8
346–456 Yes Yes 71
254–628 Yes Yes 98
346–628 Yes Yes 70
456–628 Yes Yes 97
1–628 Yes Yes 138
456–807 Yes Yes 143
628–807 Yes Yes 167
1–807 Yes Yes 200
a Fusion activity presented as a percentage of wild-type EBV fusion.
b Fusion activity presented as a percentage of wild-type Rh-LCV fusion.
c NT, not tested.ability to mediate fusion together, providing evidence of a functional
interaction between gB and the gH/gL complex.
To provide further evidence of an interaction between the gB and
gH/gL, we utilized the BiFC assay that was previously used to
demonstrate an interaction between HSV-1 gB and gH/gL. The
formation of gB oligomers was demonstrated by bright YFP ﬂuores-
cence in cells expressing the YFPN and YFPC tagged forms of gB,
conﬁrming that BiFC was a viable assay to demonstrate EBV
glycoprotein interactions. An interaction between EBV gB and gH/gL
was detected by BiFC, providing evidence that these glycoproteins
form a heterologous complex in cells. While expression of EBV gB-
YFPN and EBV gH/gL-YFPC together resulted in abundant YFP,
expression of EBV gB-YFPN and Rh gH/gL-YFPC yielded modest
ﬂuorescence in a smaller number of cells. These results support the
interpretation that EBV gB does not mediate fusion with Rh gH/gL
because the glycoproteins interact poorly.
To identify regions of gB that are involved in the interaction with
gH/gL, we generated a panel of eleven chimeras in which portions of
EBV gB were replaced with the corresponding region of Rh gB.
Following a thorough examination of the expression and localization
patterns of the chimeras, we determined that eight of the eleven
chimeras were properly processed and retained the structural
integrity of EBV gB. Analysis of these EBV/Rh gB chimeras in the
fusion assay found that insertion of Rh gB from 456 to 807 permitted
EBV gB to mediate fusion with Rh gH/gL at levels signiﬁcantly above
EBV gB. Chimeras that contained smaller portions of Rh gB from 456 to
628 and 628 to 807 were defective in mediating fusion with Rh gH/gL,
demonstrating that both regions contribute to fusion function. The
ability of some of the EBV/Rh gB chimeras to interact with gH/gL was
also analyzed using the BiFC assay. While this assay is not a
quantitative method to measure the glycoprotein interactions, we
did observe a slight increase in YFP ﬂuorescence for some of the BiFC
construct pairs. Although the difference in YFP ﬂuorescence between
the EBV/Rh gB-YFPN constructs with Rh gH/gL-YFPC was verymodest,
it is intriguing that the BiFC data correlated with the functional data
from the fusion assay. EBV/Rh (1–807) gB-YFPN and EBV/Rh (456–
807) gB-YFPN had slightly increased levels of YFP above the other
chimeras and EBV gB-YFPN. This data would suggest that these
regions are important for the interaction with Rh gH/gL. The EBV/Rh
gB chimeras containing regions (1–807) and (456–807) also exhibited
increased fusion function with Rh gH/gL when examined in the cell
fusion assay. The data obtained in this study is summarized in Table 2.
The BiFC assay used in this study has been a valuable technique to
study glycoprotein interactions in cells and has provides evidence of
an interaction between EBV gB and gH/gL. However, one of the major
limitations of this assay that has been frequently observed is the
formation of non-speciﬁc interactions (Kerppola, 2006a, 2006b). We
observed YFP ﬂuorescence between a vast majority of theFusion with
Rh gH/gLb
% YFP with
EBV gH/gL
% YFP with
Rh gH/gL
Domain of insertion
in EBV gB
2 NTc NT I and II
2 NT NT I and II
2 NT NT I and II
8 NT NT II
35 NT NT I, II, III and IV
11 NT NT II, III and IV
32 93 72 III and IV
33 NT NT I, II, III and IV
70 84 79 III, IV and V
19 83 59 V
99 93 91 I, II, III, IV and V
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chimeras that mediate fusion at low levels. The fact that the split YFP
complementation assay can stabilize weak or transient interactions
may explain why this technique was successful while other methods,
like immunoprecipitation, have been unable to detect the gB–gH/gL
interaction. The interaction observed in this study between EBV gB
and gH/gL will therefore need to be further examined to conﬁrm the
biological signiﬁcance of the interaction seen using BiFC. To control for
non-speciﬁc interactions in our BiFC studies, we used the lowest
concentration of our tagged constructs that would allow for the
detection and quantiﬁcation of YFP levels between samples. Our BiFC
experiments were completed using transiently transfected cells that
lack the EBV receptors, suggesting that the interaction we observe
between EBV gB and gH/gL occurs prior to fusion initiation. The
simultaneous analysis of the gB–gH/gL interaction using complemen-
tation studies of Rh-LCV and functional analysis of EBV/Rh gB
chimeras provided additional evidence of a functional interaction
between gB and gH/gL beyond BiFC analysis.
An interaction between gB and gH/gL was ﬁrst demonstrated by
BiFC analysis of HSV-1 glycoproteins in previous studies (Atanasiu et
al., 2007; Avitabile et al., 2007). These studies also demonstrated that
a number of homologous and heterologous glycoprotein interactions
occur between gD, gB, and gH/gL that are likely essential in the
execution of fusion. Subsequent studies have characterized regions of
HSV-1 gB important for its interaction with gH/gL, as well as recent
analysis of possible gB binding sites on the structure of the HSV-2 gH/
gL complex. Analysis of HSV-1 gB chimeras, in which portions of the
glycoprotein were replaced with the corresponding region from
human herpesvirus 8 (HHV-8) gB, found that while all chimeras could
interact with gH/gL, some exhibited a reduced ability to interact with
the complex (Avitabile et al., 2009). A separate study analyzed regions
of HSV-1 gB that are involved in the interaction between gB and gH/gL
using monoclonal gB antibodies that were able to block cell–cell
fusion, gB–gH/gL BiFC, or both. Neutralizing antibodies that map to
structural domains I, II and V of HSV-1 gB blocked the interaction
between gB and gH/gL, as demonstrated by reduced BiFC, and fusion
(Atanasiu et al., 2010). Neutralizing antibodies that map to structural
domain IV of HSV-1 gB were effective in blocking cell–cell fusion but
had no effect on the interaction between gB and gH/gL, thus
distinguishing the role of gB in mediating fusion and the interaction
with gH/gL that precedes fusion. Taken together, data from these
studies provide strong evidence that multiple sites on gB are required
for the interaction with gH/gL. The ﬁndings from the current study are
consistent with the results from these studies of HSV-1 gB, although
the speciﬁc regions of gB required for the interaction with gH/gL may
be different. We found that sites from two regions of gB (456–628 and
628–807) are both important for a functional interaction with gH/gL,
similar to the observation that multiple sites on HSV-1 gB are likely
required for the interaction with gH/gL. Our analysis of EBV gB
identiﬁed sites important for the interactionwith gH/gL in domains III,
IV, and V, while HSV-1 gB domains I, II, and V were found to be
important for the interaction with gH/gL (Avitabile et al., 2009;
Atanasiu et al., 2010). The gB binding site on the newly identiﬁed
structure of HSV-2 gH/gL was mapped to a region proximal to the gH/
gL interface (Chowdary et al., 2010). Interestingly, the crystal
structure of the HSV-2 gH/gL complex does not resemble any
previously characterized viral fusion proteins, providing further
evidence that gB acts as the sole fusogen (Chowdary et al., 2010).
Instead, it has been proposed that HSV gH/gL activates gB for fusion,
likely through a direct interaction between these glycoproteins,
similar to what we have proposed for the activation of EBV gB by
the gH/gL complex.
Results from the current study demonstrate the importance of
speciﬁc domains of gB that are required for fusion function with gH/gL
and the ability of the virus tomediate fusionwith target cells. Previous
studies have shown that EBV glycoproteins gp42 and gH/gL form atripartite complex in cells that is also essential for fusion (Li et al.,
1995; Kirschner et al., 2006; Omerovic and Longnecker, 2007).
Furthermore, analysis of Rh gL suggested that the interaction between
EBV gB and the gH/gL complex may be through a direct interaction
between gB and gL (Plate et al., 2009). Thus, it appears that multiple
interactions between the glycoproteins necessary for fusion likely
occur prior to and during EBV entry, as has also been recently
suggested for HSV (Atanasiu et al., 2010). The signiﬁcance of each
interaction and the sequence in which these events occur will need to
be the subject of further investigation to elucidate the mechanism of
EBV entry. However, based on our current knowledge of these
interactions we would propose a model in which EBV-mediated
fusion with B cells occurs through sequential binding of the
glycoproteins upon binding of gp42 to HLA class II. Receptor binding
induces a conformational change in the gp42/gH/gL tripartite complex
that allows recruitment and/or activation of gB to the glycoprotein
complex to mediate fusion through insertion of gB fusion loops into
the target cell membrane. In conclusion, our studies, in line with
studies of other herpesviruses, highlight the complexity of herpesvi-
rus-induced membrane fusion and the requirement for multiple
interactions of the virus-encoded glycoproteins for the overall
process.
Materials and methods
Cells
Chinese Hamster Ovary cells (CHO-K1) kindly provided by Nanette
Susmarski were grown in Ham's F-12 medium (BioWhittaker)
containing 10% FetalPlex animal serum complex (Gemini Bio-
Products) and 1% penicillin–streptomycin (100 U penicillin/mL,
100 μg streptomycin/mL; BioWhittaker). Cells were grown in 75-
cm2 cell culture ﬂasks and detached using either trypsin-Versene
(BioWhittaker) or Versene (phosphate-buffered saline [PBS]-1 mM
EDTA. The Daudi 29 cell line stably expressing T7 RNA polymerase
(Silva et al., 2004) were grown in RPMI 1640 medium (BioWhittaker)
containing 10% Fetal Bovine Serum (HyClone) and 1% penicillin–
streptomycin with 900 μg/mL G418 (Sigma).
Antibodies
The monoclonal gB antibody CL55 and the monoclonal antibody
E1D1 that recognizes the gH/gL complexwere generously provided by
Lindsay Hutt-Fletcher (Louisiana State Health Sciences Center,
Shreveport, LA) (Balachandran et al., 1987). The polyclonal gB
antibody was generated by immunization of rabbits with EBV gB
expression vectors (Aldevron) (McShane and Longnecker, 2004).
Construction of EBV/Rhesus gB chimeric glycoproteins
Amino acid residues 1–254, 254–346, 1–346, 346–456, 254–628,
346–628, 456–628, and 456–807 of Rh-LCV gB were ampliﬁed by PCR
using primers designed with ﬂanking restriction enzyme digest sites
unique to EBV gB in pSG5 (Stratagene). The ampliﬁed regions of Rh gB
were then ligated into the predigested EBV gB using the restriction
sites listed for each chimera: ERh gB (1–254) EcoRI/PmlI; ERh gB
(254–346) PmlI/SapI; ERh gB (1–346) EcoRI/SapI; ERh gB (346–456)
SapI/PasI; ERh gB (254–628) PmlI/PstI; ERh gB (346–628) SapI/PstI;
ERh gB (456–628) PasI/PstI; and ERh gB (456–807) PasI/AfeI. Amino
acid residues 1–628, 1–807, and 628–807 of Rh gB were isolated using
restriction enzyme digestion using the unique EcoRI, PstI, and AfeI
sites and ligated into the corresponding sites in EBV gB in pSG5. EBV/
Rh-LCV chimeras (EBV/Rh) were named based on the amino acid
sequence location of Rh gB inserted. All mutants were sequenced by
the Northwestern Biotech core sequencing facility to conﬁrm that the
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duced by PCR. DNA was isolated using Qiagen Maxi Kits (Qiagen).
Transfections
All transfections were performed using Lipofectamine 2000
transfection reagent (Invitrogen). For the fusion assay cells were
seeded into six well plates 20 h before transfection in order to reach
80% conﬂuency and transiently transfected with 0.5 μg each of EBV or
Rh gB, gH, and gL; 2 μg of gp42; and 0.8 μg of a luciferase reporter
plasmid with a T7 promoter (Okuma et al., 1999; Haan et al., 2001).
For Western blot experiments, CHO-K1 cells were plated in T-25 cm2
cell culture ﬂasks to reach 70% conﬂuency 24 h later for transfection
with 10 μg of gB. For all transfections, cells were washed 6 h after
transfection and serum-containing Ham's F-12 medium was added.
Fusion assay
The virus-free cell-based fusion assay was described previously
(Haan et al., 2001; McShane and Longnecker, 2004). Effector CHO-K1
cells were transfected with EBV or Rh-LCV glycoproteins or mutant
proteins as stated above. Twelve hours post-tranfection cells were
detached with Versene, counted with a Beckman Coulter Z1 particle
counter and mixed 1:1 with target B cells (0.25×106 per sample) into
a 24-well plate in 1 mL Ham's F-12 medium. The target cell, Daudi 29
B cells, stably express T7 RNA polymerase and were maintained in
G418 selection media (Omerovic et al., 2005). Twenty-four hours
later, the cells were washed with PBS and lysed with 100 μL of passive
lysis buffer (Promega). Luciferase was quantiﬁed in duplicate by
transferring 20 μL of lysed cells to a 96-well plate and adding 100 μL of
luciferase assay reagent (Promega) and luminescence was measured
on a Perkin–Elmer Victor plate reader. Luciferase activity was
normalized to wild-type levels and set to 100%.
Biotinylation and immunoprecipitation of biotinylated gB samples
Biotinylation of cell-surface expressed gB was performed as
previously described (Reimer et al., 2009). CHO-K1 cells were
transfected with gB as described above, washed with PBS, and
detached with 1 mM EDTA in PBS 24 h after transfection. EBV, Rh,
and chimeric gB expressing cells were washed twice with ice cold PBS
and counted using a Z1 Coulter particle counter (Beckman Coulter).
2.5×107 cells were incubated in a ﬁnal concentration of 2 mMEZ-Link
Sulfo-NHS-LC-Biotin (Pierce) and rotated at 4 °C for 30 min. Samples
werewashed three timeswith PBS containing 100 mMGlycine to stop
the reaction before the cells were pelleted and resuspended in 1%
Triton X-100 lysis buffer. Cell lysates were incubated at 4 °C for 30 min
before insoluble material was removed by centrifugation at
13,000 rpm at 4 °C. 20 μL of protein G-Sepharose beads (GE Health-
care)were rotatedwith 1 μL CL55 gB antibody and lysates overnight at
4 °C to precipitate gB. Beads were washed four times with 1 mL of
Triton X-100 lysis buffer. Bound biotinylated proteinwas eluted in SDS
buffer without β-mercaptoethanol and boiled at 70 °C for 10 min.
SDS-PAGE and Western blot analysis of gB
CHO-K1 cells were transfected as described above and washed
twice with PBS 24 h after transfection. Cells were detached using
1 mM EDTA in PBS, pelleted by centrifugation, and counted using a Z1
Coulter particle counter (Beckman Coulter). Cell pellets were lysed
with 1% Triton X-100 lysis buffer (at 1 mL lysis buffer per 10 million
cells) and insoluble material was removed by centrifugation at
13,000 rpm at 4 °C. For intracellular protein expression samples
were mixed with SDS buffer containing β-mercaptoethanol, boiled at
95 °C for 10 min and pelleted by centrifugation. For analysis of
oligomer formation, SDS buffer lacking β-mercaptoethanol was used.All gB sample supernatants were separated on 7.5% Criterion sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels (Bio-Rad) and
transferred to Immobilon membranes (Millipore). Membranes were
blocked in Tris-buffered saline plus 1% Tween-20 with 5% milk for
30 min and probed overnight at 4 °C with the polyclonal gB antibody
(1:2000 dilution). Membranes were washed in Tris-buffered saline
plus Tween-20, and secondary HRP-conjugated anti-rabbit antibody
was applied for 0.5 h at room temperature. Membranes were then
washed and blots were incubated in ECL Western Blotting Detection
reagents (GE Healthcare) and exposed to Hyperﬁlm (GE Healthcare).
Construction of EBV glycoproteins with YFP fragments
The constructs of EBV glycoproteinswith the YFP amino or carboxyl
terminal fragmentswere derived from the previously describedHSV-1
split YFP glycoproteins that were generously provided by Gary Cohen
and Roselyn Eisenberg (Atanasiu et al., 2007). The amino and carboxyl
terminal fragments of a variant enhanced yellow ﬂuorescent protein
(EYFP), called Venus, were PCR-ampliﬁed and ligated into the PCAGGS
expression vector between the sites KpnI and XhoI. The N-terminal
portion of EYFP (YFPN) contains residues 1–173 and the C-terminal
portion of EYFP (YFPC) contains residues 173–239. EBV glycoproteins
gB and gH and Rh-LCV glycoprotein gH were PCR-ampliﬁed using
primers that excluded the stop codon. The glycoproteins were ligated
in frame with the N or C-terminal portions of the EYFP open reading
frame. EBV gB and Rh gHwere ligated in frame into the PCAGGS-YFPN
and PCAGGS-YFPC plasmids between the sites EcoRI and KpnI. EBV gH
was ligated in frame into the PCAGGS-YFPN and PCAGGS-YFPC
plasmids at the ClaI site. All glycoprotein constructs were sequenced
by the Northwestern Biotech core sequencing facility to conﬁrm the
appropriate sequences were present and no mutations were intro-
duced. DNA was isolated using Qiagen Maxi Kits (Qiagen).
Construction of EBV/Rh chimeric gB glycoproteins with YFP N-terminal
fragment
EBV/Rh gB chimeras selected for further analysis were digested
with their corresponding restriction enzyme pairs: ERh gB (456–628)
PasI/PstI; ERh gB (628–807) PstI/AfeI; ERh gB (456–807) PasI/AfeI,
and ERh gB (1–807) EcoRI/AfeI. The Rh gB inserts were ligated into the
predigested EBV gB-YFPN glycoprotein construct in the pSG5
expression vector. All chimeric YFPN glycoprotein constructs were
sequenced by the Northwestern Biotech core sequencing facility and
DNA isolated using Qiagen Maxi Kits (Qiagen).
Bimolecular ﬂuorescence complementation (BiFC) analysis
CHO-KI cells were seeded on glass coverslips in 6-well dishes and
transfected using Lipofectamine 2000 as described above. For each
glycoprotein split YFP construct, 200 ng of DNA was transfected, with
the PCAGGS expression vector used to equalize DNA levels between
samples. Media was replaced after 6 h of transfection, and cells
washed with PBS after 20 h. Cells were ﬁxed with 4% paraformalde-
hyde and permeabilized with 0.1% Triton X-100, followed by staining
with either the rabbit polyclonal gB antibody (1:500 dilution) or the
monoclonal gH/gL complex speciﬁc E1D1 antibody (1:50 dilution).
Anti-rabbit and anti-mouse secondary antibodies carrying either a cy3
or cy5 ﬂuorescent tag (Jackson Immuno) were used at a 1:500
dilution. Coverslips were mounted with ProLong Gold Antifade
(Invitrogen) and imaged on a Zeiss LSM 510 META laser scanning
confocal microscope. A UV 405 nm laser, Argon 488/543 laser, and
HeNe 633 laser were used to excite the ﬂuorescence of DAPI, YFP, cy3,
and cy5, respectively. Images were collected using a 40× oil
immersion objective, at 1024×1024 pixel resolution and a 16-bit
intensity scale. The settings were adjusted while imaging the control
samples and not modiﬁed between the remaining samples.
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